Oncolytics Biotech Inc (ONCY)

0.28

0.01 3.36

OTC : Health Care

Jan 8, 2016 3:59 PM EST

Prev Close	0.27
Open	0.27
Day Low/High	0.27 / 0.29
52 Wk Low/High	0.24 / 1.40
Volume	69.43K
Avg Volume	361.10K

Exchange	OTC
Shares Outstanding	117.98M
Market Cap	34.19M
EPS	-0.18
Div & Yield	N.A. (N.A)

Latest News

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

OTC Markets Group Welcomes Oncolytics Biotech® Inc. To OTCQX

Oncolytics Biotech® Inc. Announces Receipt Of Qualification For Trading On The OTCQX And Nasdaq Notice Of Delisting

Oct 29, 2015 6:30 AM EDT

Media Advisory - Oncolytics Biotech® Inc. To Participate In The 14th Annual BIO Investor Forum

Oct 20, 2015 6:45 AM EDT

Oncolytics Biotech® Inc. Announces Phase 1b Study In Advanced Pancreatic Cancer

Oct 20, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Completion Of Enrollment In Randomized Phase II Prostate Cancer Study

Oct 6, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Collaborators Present Data From Clinical Study In Multiple Myeloma

Sep 25, 2015 6:30 AM EDT

Media Advisory - Oncolytics Biotech® Inc. To Participate In The Baird 2015 Healthcare Conference

Sep 9, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Collaborators To Present Survival Data From REO 016 Study In Non-Small Cell Lung Cancer

Aug 27, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Completion Of Enrollment In Randomized Phase II Non-Small Cell Lung Cancer Study

Aug 26, 2015 6:30 AM EDT

MEDIA ADVISORY - Oncolytics Biotech® Inc. To Participate In The 35th Annual Canaccord Genuity Growth Conference

Aug 12, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data At The 9th International Conference On Oncolytic Virus Therapeutics

Jun 15, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Voting Results From Its Annual Meeting Of Shareholders

Jun 12, 2015 5:00 PM EDT

Oncolytics Biotech® Inc. Provides Update At AGM On Planned Registration Program For REOLYSIN®

Jun 8, 2015 4:00 PM EDT

/C O R R E C T I O N -- Oncolytics Biotech Inc./

Jun 6, 2015 3:18 PM EDT

5 Stocks Under $10 Ready to Spike Higher

These under-$10 stocks look poised to breakout out and trade higher from current levels.

May 29, 2015 8:51 AM EDT

Oncolytics Biotech® Inc. Announces Phase 1 Study In Pediatric Patients With Brain Tumors

May 19, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Gastric Cancer

May 6, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Status From The EMA For Pancreatic Cancer

Apr 29, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Extension To Regain Compliance With Nasdaq's Minimum Bid Price Rule

Apr 28, 2015 6:22 PM EDT

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data At The 2015 AACR Annual Meeting

Apr 20, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Malignant Gliomas

Apr 17, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Presents At UK Immuno-oncology Meeting

Apr 15, 2015 6:30 AM EDT

Media Advisory - Oncolytics Biotech® Inc. To Participate In The 14th Annual Needham Healthcare Conference

Apr 13, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Filing For Orphan Drug Designation With The U.S. FDA For Gastric Cancer

Apr 7, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Presents At The 2015 Immune Checkpoint Inhibitors Meeting

Mar 26, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Status From The EMA For Ovarian Cancer

Mar 25, 2015 6:30 AM EDT

Oncolytics Biotech® Inc. Collaborators Present Preclinical Data On The Combination Of REOLYSIN® And Radiotherapy In Melanoma At The Irish Association For Cancer Research Conference

Mar 5, 2015 6:30 AM EST

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer

Mar 3, 2015 6:30 AM EST

Oncolytics Biotech® Inc. Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube

Mar 2, 2015 6:30 AM EST

From Our Partners

Oncolytics downgraded to Neutral with 75c price target at Piper Jaffray

The Fly

Oncolytics downgraded to Neutral from Overweight at Piper Jaffray

The Fly

Oncolytics Biotech's Reolysin shows positive results in pancreatic cancer

The Fly